Spending on Telehealth Solutions in North America through 2007 - 2012 (Databook)
| Publication Date | June 2007 |
|---|---|
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 11 |
| ISBN Number | not applicable |
| Product Code | DAT06119 |
Summary
Introduction
The telehealth market will continue to grow as the population, particularly the elderly and chronically ill, and technology adoption increase.
Scope
- Identifies potential growth areas for the telehealth market
- Quantifies spending on telehealth by application
- Segments telehealth spending by geography and technology
Highlights
The uptake of telehealth will increase rapidly in the next five years and will continue to increase after 2012.
Policy issues are among the reasons why the telehealth market is not growing as quickly as it could be.
Initial investments in telehealth will be for clinical applications, but homecare applications will drive the future growth of the market.
Reasons to Purchase
- Understand the current size of the telehealth market in North America
- Gain insight into the projected direction of telehealth spending
- Recognize the differences in telehealth spending across geographies, applications and technologies
Content
- Overview
- Catalyst
- Summary
- Methodology
- Telehealth Spending In North America Through 2012
- Introduction
- Telehealth Spending In North America Through 2012
- Telehealth Spending In The Us Through 2012
- Clinical Telehealth Spending In The Us Through 2012
- Homecare Telehealth Spending In The Us Through 2012
- Telehealth Spending In Canada Through 2012
- Clinical Telehealth Spending In Canada Through 2012
- Homecare Telehealth Spending In Canada Through 2012
- Appendix
- Definitions
- Further Reading
- Ask The Analyst
- Datamonitor Consulting
About this Product
Delivery Details
PDF:Delivered by email usually within 4 to 8 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.
Related Products
- AstraZeneca’s Crestor Could Revolutionise Heart Disease Treatment >>
- Sanofi-Aventis and Pfizer Stop Development of a Class of Anti-obesity drugs >>
- Pharma Companies turn Webwards to Recruit Patients as 90% of Clinical Trials Face Delay >>
- Have your Healthcare Costs Reduced with Personalized Healthcare >>
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories















